Hbm Holdings Ltd
HKEX:2142
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
Hbm Holdings Ltd
HKEX:2142
|
HK |
|
Geberit AG
SIX:GEBN
|
CH |
|
Camden Property Trust
NYSE:CPT
|
US |
|
B
|
Benara Bearings and Pistons Ltd
BSE:541178
|
IN |
|
H
|
Himalaya Shipping Ltd
OSE:HSHIP
|
BM |
|
C
|
Cirsa Enterprises SAU
MAD:CIRSA
|
ES |
|
Stanley Black & Decker Inc
NYSE:SWK
|
US |
|
L
|
Lionhead Technology Development Co Ltd
SSE:600539
|
CN |
|
Shell PLC
LSE:SHEL
|
UK |
|
Jindal Worldwide Ltd
NSE:JINDWORLD
|
IN |
|
R
|
Riyadh Cables Group Company CJSC
SAU:4142
|
SA |
|
I
|
Insimbi Industrial Holdings Ltd
JSE:ISB
|
ZA |
|
M
|
Myoung Shin Industrial Co Ltd
KRX:009900
|
KR |
|
Qube Holdings Ltd
ASX:QUB
|
AU |
|
Andrews Sykes Group PLC
LSE:ASY
|
UK |
|
G
|
Geotrans SA
WSE:GTS
|
PL |
Hbm Holdings Ltd
HBM Holdings Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutics in the fields of immuno-oncology and immunology diseases. The Company’s products include batoclimab, mainly used for immune thrombocytopenia (ITP), graves’ ophthalmopathy (GO), myasthenia gravis (MG), neuromyelitis optica spectrum disorder (NMOSD); and tanfanercept, mainly used for dry eye disease (DED). In addition, the Company researches and develops immuno-oncology portfolio, including internally developed next-generation immune-oncology assets targeting immune-desert, immune-excluded and inflamed tumors.
HBM Holdings Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutics in the fields of immuno-oncology and immunology diseases. The Company’s products include batoclimab, mainly used for immune thrombocytopenia (ITP), graves’ ophthalmopathy (GO), myasthenia gravis (MG), neuromyelitis optica spectrum disorder (NMOSD); and tanfanercept, mainly used for dry eye disease (DED). In addition, the Company researches and develops immuno-oncology portfolio, including internally developed next-generation immune-oncology assets targeting immune-desert, immune-excluded and inflamed tumors.
